Further investigations are needed to elucidate the utility of serum HMGB1 as a predictive biomarker and molecular target for preventing triggered AE, including postoperative AE-ILD, in patients with lung cancer and ILD. This evidence concerns the gene HMGB1 and lung carcinoma.